Vor Biopharma (NASDAQ:VOR) Director Ra Capital Management, L.P. Sells 165,150 Shares

Key Points

• Ra Capital Management sold roughly 3.00 million Vor Biopharma shares in April (including 165,150 shares on April 22 at $15.77), totaling about $49.4 million in transactions and reducing its stake by 6.43% to 2,402,095 shares valued at ~$37.9 million.
• VOR traded at $13.81 midday with a market cap of $674.6 million (50-day MA $14.89, 200-day MA $15.65), and analysts hold a mixed but overall "Moderate Buy" consensus with a $50.56 average target price.

Vor Biopharma Inc. (NASDAQ:VOR - Get Free Report) Director Ra Capital Management, L.P. sold 165,150 shares of the firm's stock in a transaction on Wednesday, April 22nd. The shares were sold at an average price of $15.77, for a total transaction of $2,604,415.50. Following the completion of the transaction, the director directly owned 2,402,095 shares of the company's stock, valued at $37,881,038.15. This represents a 6.43% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Ra Capital Management, L.P. also recently made the following trade(s):

• On Monday, April 20th, Ra Capital Management, L.P. sold 171,963 shares of Vor Biopharma stock. The shares were sold at an average price of $15.77, for a total transaction of $2,711,856.51.
• On Friday, April 17th, Ra Capital Management, L.P. sold 458,411 shares of Vor Biopharma stock. The shares were sold at an average price of $16.28, for a total transaction of $7,462,931.08.
• On Monday, April 13th, Ra Capital Management, L.P. sold 530,610 shares of Vor Biopharma stock. The stock was sold at an average price of $16.15, for a total transaction of $8,569,351.50.
• On Wednesday, April 15th, Ra Capital Management, L.P. sold 53,644 shares of Vor Biopharma stock. The stock was sold at an average price of $16.01, for a total transaction of $858,840.44.
• On Tuesday, April 14th, Ra Capital Management, L.P. sold 153,735 shares of Vor Biopharma stock. The stock was sold at an average price of $15.97, for a total transaction of $2,455,147.95.
• On Friday, April 10th, Ra Capital Management, L.P. sold 828 shares of Vor Biopharma stock. The stock was sold at an average price of $15.75, for a total transaction of $13,041.00.
• On Thursday, April 9th, Ra Capital Management, L.P. sold 135,201 shares of Vor Biopharma stock. The stock was sold at an average price of $16.59, for a total transaction of $2,242,984.59.
• On Wednesday, April 8th, Ra Capital Management, L.P. sold 484,104 shares of Vor Biopharma stock. The stock was sold at an average price of $16.48, for a total transaction of $7,978,033.92.
• On Monday, April 6th, Ra Capital Management, L.P. sold 589,257 shares of Vor Biopharma stock. The stock was sold at an average price of $16.59, for a total transaction of $9,775,773.63.
• On Thursday, April 2nd, Ra Capital Management, L.P. sold 260,000 shares of Vor Biopharma stock. The stock was sold at an average price of $18.23, for a total transaction of $4,739,800.00.

Vor Biopharma Price Performance

VOR stock traded down $0.81 during midday trading on Friday, reaching $13.81. 1,074,648 shares of the company were exchanged, compared to its average volume of 1,033,286. The business has a 50-day moving average price of $14.89 and a two-hundred day moving average price of $15.65. Vor Biopharma Inc. has a one year low of $2.62 and a one year high of $65.80. The firm has a market capitalization of $674.62 million, a price-to-earnings ratio of -0.04 and a beta of 1.92.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on VOR shares. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Vor Biopharma in a research report on Wednesday, January 21st. Citigroup started coverage on shares of Vor Biopharma in a research report on Friday, January 9th. They set a "buy" rating and a $50.00 price objective for the company. HC Wainwright reduced their price objective on shares of Vor Biopharma from $32.00 to $31.00 and set a "buy" rating for the company in a research report on Wednesday, April 15th. Wall Street Zen raised Vor Biopharma from a "strong sell" rating to a "hold" rating in a report on Saturday, April 4th. Finally, Jefferies Financial Group began coverage on shares of Vor Biopharma in a research report on Monday, March 30th. They issued a "buy" rating and a $50.00 target price for the company. Two investment analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating, four have given a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $50.56.

Institutional Investors Weigh In On Vor Biopharma

Institutional investors have recently modified their holdings of the business. China Universal Asset Management Co. Ltd. bought a new stake in shares of Vor Biopharma in the fourth quarter valued at about $36,000. Goldman Sachs Group Inc. boosted its position in shares of Vor Biopharma by 218.2% in the first quarter. Goldman Sachs Group Inc. now owns 84,945 shares of the company's stock valued at $61,000 after acquiring an additional 58,247 shares during the period. XTX Topco Ltd bought a new stake in shares of Vor Biopharma in the second quarter valued at about $66,000. Chung Wu Investment Group LLC bought a new stake in shares of Vor Biopharma in the fourth quarter valued at about $109,000. Finally, Susquehanna Portfolio Strategies LLC bought a new stake in shares of Vor Biopharma in the fourth quarter valued at about $134,000. Institutional investors own 97.29% of the company's stock.

Vor Biopharma Company Profile

Vor Biopharma, Inc is a clinical-stage biotechnology company focused on the development of next-generation, allogeneic cell therapies for patients with hematologic malignancies. The company's proprietary platform leverages genome editing to engineer donor-derived hematopoietic stem cells (HSCs), enabling the generation of off-the-shelf therapeutic candidates designed to overcome limitations of traditional autologous and matched donor transplants. By targeting key surface antigens and reconstituting the patient's immune system, Vor aims to deliver curative potential with reduced treatment timelines and broader patient applicability.

The lead program, VOR33, is a CD33-edited HSC product candidate being evaluated in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.